Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Net Margin: 2020-2025

Historic Net Margin for Relay Therapeutics (RLAY) over the last 3 years, with Jun 2025 value amounting to -10,301.62%.

  • Relay Therapeutics' Net Margin was N/A to -10,301.62% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,693.16%, marking a year-over-year change of. This contributed to the annual value of -3,374.86% for FY2024, which is 203627.00% down from last year.
  • Relay Therapeutics' Net Margin amounted to -10,301.62% in Q2 2025, which was down 926.61% from -1,003.46% recorded in Q1 2025.
  • In the past 5 years, Relay Therapeutics' Net Margin registered a high of 8,349,600.00% during Q4 2023, and its lowest value of -82,765.55% during Q2 2023.
  • Moreover, its 3-year median value for Net Margin was -1,003.46% (2025), whereas its average is 1,173,250.90%.
  • In the last 5 years, Relay Therapeutics' Net Margin tumbled by 428,647,408bps in 2021 and then spiked by 837,627,154bps in 2023.
  • Over the past 5 years, Relay Therapeutics' Net Margin (Quarterly) stood at -11,897.00% in 2021, then crashed by 1,477,454bps to -26,671.54% in 2022, then skyrocketed by 837,627,154bps to 8,349,600.00% in 2023, then spiked by 4,088,512bps to -813.55% in 2024, then slumped by 18,991bps to -10,301.62% in 2025.
  • Its Net Margin was -10,301.62% in Q2 2025, compared to -1,003.46% in Q1 2025 and -813.55% in Q1 2024.